Nuvectis Pharma Stock Price Prediction

NVCT Stock  USD 4.95  0.15  2.94%   
The RSI of Nuvectis Pharma's share price is above 70 at this time. This indicates that the stock is becoming overbought or overvalued. The idea behind Relative Strength Index (RSI) is that it helps to track how fast people are buying or selling Nuvectis, making its price go up or down.

Oversold Vs Overbought

74

 
Oversold
 
Overbought
The successful prediction of Nuvectis Pharma's future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Nuvectis Pharma, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Nuvectis Pharma's stock price prediction:
EPS Estimate Next Quarter
(0.27)
Wall Street Target Price
22
EPS Estimate Current Quarter
(0.25)
Using Nuvectis Pharma hype-based prediction, you can estimate the value of Nuvectis Pharma from the perspective of Nuvectis Pharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Nuvectis Pharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Nuvectis because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Nuvectis Pharma after-hype prediction price

    
  USD 5.17  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Nuvectis Pharma Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Nuvectis Stock please use our How to Invest in Nuvectis Pharma guide.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Nuvectis Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
0.398.9417.49
Details
Naive
Forecast
LowNextHigh
0.062.8811.43
Details
3 Analysts
Consensus
LowTargetHigh
18.8120.6722.94
Details
Earnings
Estimates (0)
LowProjected EPSHigh
0.000.000.00
Details

Nuvectis Pharma After-Hype Price Prediction Density Analysis

As far as predicting the price of Nuvectis Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Nuvectis Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Nuvectis Pharma, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Nuvectis Pharma Estimiated After-Hype Price Volatility

In the context of predicting Nuvectis Pharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Nuvectis Pharma's historical news coverage. Nuvectis Pharma's after-hype downside and upside margins for the prediction period are 0.26 and 13.72, respectively. We have considered Nuvectis Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
4.95
5.17
After-hype Price
13.72
Upside
Nuvectis Pharma is relatively risky at this time. Analysis and calculation of next after-hype price of Nuvectis Pharma is based on 3 months time horizon.

Nuvectis Pharma Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Nuvectis Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Nuvectis Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Nuvectis Pharma, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.10 
8.56
  0.12 
 0.00  
10 Events / Month
17 Events / Month
In about 10 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
4.95
5.17
1.37 
707.44  
Notes

Nuvectis Pharma Hype Timeline

Nuvectis Pharma is now traded for 4.95. The entity has historical hype elasticity of 0.12, and average elasticity to hype of competition of 0.0. Nuvectis is forecasted to increase in value after the next headline, with the price projected to jump to 5.17 or above. The average volatility of media hype impact on the company the price is over 100%. The price appreciation on the next news is projected to be 1.37%, whereas the daily expected return is now at -0.1%. The volatility of related hype on Nuvectis Pharma is about 28533.33%, with the expected price after the next announcement by competition of 4.95. Net Loss for the year was (22.26 M) with profit before overhead, payroll, taxes, and interest of 0. Given the investment horizon of 90 days the next forecasted press release will be in about 10 days.
Check out Nuvectis Pharma Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Nuvectis Stock please use our How to Invest in Nuvectis Pharma guide.

Nuvectis Pharma Related Hype Analysis

Having access to credible news sources related to Nuvectis Pharma's direct competition is more important than ever and may enhance your ability to predict Nuvectis Pharma's future price movements. Getting to know how Nuvectis Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Nuvectis Pharma may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
REPLReplimune Group 0.28 10 per month 2.86  0.11  7.38 (5.60) 15.63 
LYRALyra Therapeutics(0.01)4 per month 0.00 (0.10) 8.00 (10.00) 41.07 
KRONKronos Bio 0.01 9 per month 0.00 (0.06) 5.56 (6.25) 16.20 
GOSSGossamer Bio(0.02)8 per month 0.00 (0.13) 6.06 (4.76) 17.73 
OLMAOlema Pharmaceuticals(0.37)4 per month 0.00 (0.12) 5.58 (5.89) 19.19 
LRMRLarimar Therapeutics(0.49)9 per month 0.00 (0.06) 10.87 (9.55) 26.71 
CNTACentessa Pharmaceuticals PLC 0.32 9 per month 3.06  0.11  8.37 (5.69) 21.09 
OBIOOrchestra BioMed Holdings(0.35)7 per month 5.87 (0.02) 7.24 (7.67) 25.42 
GLUEMonte Rosa Therapeutics(0.25)9 per month 3.86  0.08  10.11 (8.18) 102.66 
NAMSNewAmsterdam Pharma 0.71 9 per month 3.34  0.07  5.33 (3.97) 29.23 
IVAInventiva Sa(0.08)3 per month 4.09  0.03  7.26 (6.92) 49.76 
CGEMCullinan Oncology LLC 1.25 10 per month 0.00 (0.17) 5.88 (7.24) 17.85 
CMPXCompass Therapeutics(0.15)4 per month 4.49  0.06  11.19 (5.92) 29.38 
IKNAIkena Oncology(0.05)4 per month 1.39 (0.07) 1.81 (1.74) 13.50 
AVTEAerovate Therapeutics(0.02)3 per month 2.13  0.14  5.58 (3.86) 19.11 
ELYMEliem Therapeutics 0.25 4 per month 0.00 (0.20) 6.21 (9.35) 34.87 
DBTXDecibel Therapeutics 0.01 1 per month 4.12  0.05  7.85 (7.45) 26.09 
ANEBAnebulo Pharmaceuticals 0.03 5 per month 0.00 (0.02) 8.85 (11.48) 76.00 
HOWLWerewolf Therapeutics(0.02)6 per month 4.85 (0.01) 9.21 (8.75) 49.02 
EWTXEdgewise Therapeutics 0.32 10 per month 2.85  0.11  6.65 (4.70) 61.02 
CELCCelcuity LLC(0.36)7 per month 0.00 (0.16) 4.02 (5.73) 16.97 
CCCCC4 Therapeutics(0.35)10 per month 0.00 (0.11) 9.57 (7.98) 23.66 

Nuvectis Pharma Additional Predictive Modules

Most predictive techniques to examine Nuvectis price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Nuvectis using various technical indicators. When you analyze Nuvectis charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Nuvectis Pharma Predictive Indicators

The successful prediction of Nuvectis Pharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Nuvectis Pharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Nuvectis Pharma based on analysis of Nuvectis Pharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Nuvectis Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Nuvectis Pharma's related companies.
 2010 2022 2023 2024 (projected)
Current Ratio2.413.32.752.26
Net Debt To EBITDA0.451.040.840.62

Story Coverage note for Nuvectis Pharma

The number of cover stories for Nuvectis Pharma depends on current market conditions and Nuvectis Pharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Nuvectis Pharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Nuvectis Pharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Nuvectis Pharma Short Properties

Nuvectis Pharma's future price predictability will typically decrease when Nuvectis Pharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Nuvectis Pharma often depends not only on the future outlook of the potential Nuvectis Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Nuvectis Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding15.6 M
Cash And Short Term Investments19.1 M

Additional Tools for Nuvectis Stock Analysis

When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.